With the new focus on tumorigenesis and persistent atypical signaling, CCR5 is currently being used as an emerging therapeutic target for most metastatic cancer, with current clinical experiments in breast and colon cancers [21, 22]. Here, CCR5 is linked to metastatic malignant neoplasm.